4H-QUINOLIZIN-4-ONE COMPOUNDS EXHIBITING THERAPEUTIC ACTIVITIES

Abstract: This invention provides novel 4H-quinolizin-4-one compounds which exhibit a selective inhibitory activity against IgE-antibody formation, and have utility for treatment of diseases associated with IgE formation in mammals, such as allergic bronchial asthma, allergic rhinitis, atopic dermatitis, hypersensitiveness, and the like.

Description: This invention relates to novel quinolizinone derivatives which are useful as therapeutic agents. More particularly, this invention provides 4H-quinolizin-4-one compounds which exhibit selective inhibitory activities relative to IgE-antibody formation, and which have properties suitable for their use as drugs for the treatment of diseases associated with IgE such as allergic bronchial asthma, allergic rhinitis, atopic dermatitis and hypersensitiveness. Several classes of immunoglobulin(s) [hereinafter referred to as Ig(s)] are well known as antibodies concerned with immune response. Most Igs, especially immunoglobulin G (hereinafter referred to as IgG) which is one class of Igs, play an important role in the self-defence mechanisms of mammals against foreign substances such as viruses, bacteria and tumours. However, immunoglobulin E (hereinafter referred to as IgE) which is another class of Igs, has been confirmed to be primarily responsible for diseases such as allergic bronchial asthma, allergic rhinitis, atopic dermatitis and hypersensitiveness, (Journal of Immunology, Vol. 10, p 445. 1925, Journal of Immunology, Vol. 97, p 75, 1966). It also has been confirmed that the serum concentrations of IgE in most allergic patients suffering from those diseases are generally higher than those in normal persons. Therefore, for a causal and useful treatment of such diseases associated with IgE, selective inhibitors of IgE formation are being actively sought. The prospective inhibitors preferably would not inhibit excessively any class of Igs except IgE for the reason mentioned above. Up to the present time, various compounds have been reported in the literature as inhibiting IgE formation such as [Japanese Patent Application (OPI) No. 76/87 (the term "OPI" used herein refers to an unexamined Japanese Patent Application); U.S. Patents Nos. 4,395,405 and 4,691,018; British Patent Application No. 2,020,665 (A); and J. Med. Chem. Vol, 25, No. 12, pages 1495-1499, 1982]. Of particular interest with respect to the present invention are the publications which disclose compounds having a substituted 4H-quinolizin-4-one nucleus. Processes for the production of 1-, 2- and 3-substituted 4H-quinolizin-4-one derivatives are described in Yakugaku Zasshi, Vol. 89, No. 2, pages 203-208, 1968, ibid. Vol. 90, No. 2, pages 127-131, 1970, ibid. Vol. 91, No. 12, pages 1275-1278, 1971, ibid. Vol. 94, No. 1, pages 44-49, 1974, 1977, Chem. Pharm. Bull, Vol. 18, No. 1, pages 124-127, 1970, ibid. Vol. 21, No. 5, pages 921-925, 1973, J. Heterocycl. Chem., Vol. 10, No. 2, pages 139-142, 1973, J. Chem. Soc. (c), pages 1143-1146, 1969, Monatish. Chem., Vol. 114, pages 485-493, 1983. The anti-tumour activity of 1-, 2- and 3-substituted 4H-quinolizin-4-one derivatives of the formula: where R is methylthio, piperidino, N,N-diethyl aminoethylamino or benzylamino is disclosed in Yakugaku Zasshi, Vol 97, No. 9, pages 1039-1045, 1988. European Patent Application 157346 (A₂) and Japanese Patent Application (OPI) No. 22482/85 which are counterparts of British Patent Application Nos. 8408292 and 8429710, filed March 30, 1984 and November 23, 1984, respectively, disclose quinolizinone derivatives having an inhibitory activity on allergies and ulcers, which derivatives correspond to the formula: where R¹ is carboxy, amidated carboxy, cyano, thiocarbamoyl or tetrazolyl; R⁷ is hydrogen or aryl; R² is hydrogen, hydroxy, lower alkyl or lower alkoxy; R³ is hydrogen, hydroxy, lower alkyl, lower alkoxy, lower alkenyloxy, aryl which may have suitable substituents arylthio, aroyl, ar(lower)alkyl, arenesulfonyl, arylamino which may have a suitable substituent or aryloxy; and R² and R³ can be located at any place on the quinolizine ring and can be linked together to form ―CH₂CH₂CH₂―, ―CH=CH― or ―CH=CH-CH=CH― ; and pharmaceutically acceptable salts thereof. Japanese Patent Application (OPI) No. 77385/87 which is a counterpart of United States Patent Application Serial No. 770953 filed August 30, 1985, discloses quinolizinone derivatives having inhibitory activity on allergies and ulcers, which derivatives correspond to the formula: where R¹ is carboxy, tetrazolycarbamoyl or amino-substituted triazolycarbamoyl; R² is hydrogen or lower alkoxy; R³ is hydrogen, aroyl, aryl, carboxy or protected carboxy; R⁴ is hydrogen or hydroxy; with the proviso that (i) when R³ is hydrogen, R⁴ is hydroxy, (ii) when R³ is aryl, R¹ is amino-substituted triazolylcarbamoyl and (iii) when R³ is aroyl, R² is lower alkoxy; and pharmaceutically acceptable salts thereof. United States Patent No. 4,650,804 which is a counterpart of British Patent Application Nos. 8408292 and 8429710, filed March 30, 1984 and November 23, 1984, respectively, disclose quinolizinone derivatives having inhibitory activity on allergies and ulcers, which derivatives correspond to the formula: where R¹ is tetrazolycarbamoyl; R⁷ is hydrogen or aryl selected from phenyl, tolyl, xylyl, cumenyl, naphthyl and biphenylyl; R² is hydrogen, hydroxy, lower alkyl or lower alkoxy; R³ is hydrogen, hydroxy, lower alkyl, lower alkoxy, lower alkenyloxy, phenyl, naphthyl, biphenylyl, phenyl having one or more substituents selected from halogen, lower alkyl and lower alkoxy, arylthio selected from phenylthio, tolylthio, xylylthio, cumenylthio, naphthylthio and biphenylylthio, aroyl selected from benzoyl, touoyl and naphthoyl ar(lower)alkyl selected from phenyl(lower)alkyl, tolyl(lower)alkyl, xylyl(lower)alkyl, cumenyl(lower)alkyl, naphthyl(lower)alkyl and biphenylyl(lower)alkyl, arenesulfonyl selected from benzenesulfonyl and p-toluenesulfonyl, arylamino selected from phenylamino, naphthylamino, biphenylylamino, phenylamino having lower alkyl on the nitrogen atom or aryloxy selected from phenoxy and tolyoxy; or pharmaceutically acceptable salts thereof. United States Patent No. 4,698,349 filed August 30, 1985, disclose quinolizinone derivatives having inhibitory activity on allergies and ulcers, which derivatives correspond to the formula: where R¹ carboxy, carbamoyl, phenylcarbamoyl which may have hydroxy, cyano or thiocarbamoyl; R⁷ is hydrogen or aryl selected from phenyl, tolyl, xylyl, cumenyl, naphthyl and biphenylyl; R² is hydrogen, hydroxy, lower alkyl or lower alkoxy; R³ is hydrogen, hydroxy, lower alkyl, lower alkoxy, lower alkenyloxy, phenyl, naphthyl, biphenylyl, phenyl having one or more substituents selected from halogen, lower alkyl and lower alkoxy, arylthio selected from phenylthio, tolylthio, xylylthio, cumenylthio, naphthylthio and biphenylylthio, aroyl selected from benzoyl, toluoyl and naphthoyl ar(lower)alkyl selected from phenyl(lower)alkyl, tolyl(lower)alkyl, xylyl(lower)alkyl, cumenyl(lower)alkyl, naphthyl(lower)alkyl and biphenylyl(lower)alkyl, arene sulfonyl selected from benzenesulfonyl and p-toluene-sulfonyl, arylamino selected from phenylamino, naphthylamino, biphenylylamino, phenylamino having lower alkyl on the nitrogen atom or aryloxy selected from phenoxy and tolyoxy; or pharmaceutically acceptable salts thereof. In none of the publications described above is there any disclosure or suggestion that novel substituted 4H-quinolizin-4-one of the type provided by the present invention might exhibit an inhibitory activity against IgE formation in mammals. As an invention related to the present invention, the present inventors have been filed U.S. Patent Application S.N. 147,549, on January 25, 1988. We have now developed novel quinolizinone derivatives which exhibit selective inhibitory activities against IgE formation when administered to humans and pharmaceutical compositions comprising these quinolizinone derivatives. The present invention provides novel 4H-quinolizin-4-one derivatives of the general formula: where R is an alkyl group or a phenylalkyl group; A is a substituted or unsubstituted phenyl group or a heterocyclic group which is bonded to the quinolizine ring at the nitrogen atom of the heterocyclic ring. In the above and subsequent description of the present specification, the terms used in the definitions of the symbols have the following meanings. The terms "alkyl" and the "alkyl" moiety in "phenyl-alkyl", "hydroxyalkyl", "alkylthio" and "morpholino-carbonyalalkyl" refer to a straight or branched alkyl group having 1 to 6 carbon atoms. The term "alkoxy" refers to a straight or branched alkoxy group having 1 to 6 carbon atoms. The term "acyl" refers to an aliphatic acyl group such as acetyl, propionyl or cyclohexylacetyl, an aromatic acyl group such as benzoyl which may have suitable substituents on the ring, or an aromatic aliphatic acyl group such as phenylacetyl or phenyl-propionyl which may have suitable substituents on the ring and/or chain. An acyl group has a content of 2 to 12 carbon atoms. The term "a substituted or unsubstituted phenyl group" refers to a substituted or unsubstituted phenyl group which may 1 to 3 substituents selected from a halogen atom, an alkyl group, an alkoxy group, hydroxy group, nitro group, amino group, an acylamino group, an alkylthio group, phenyl group, benzoyl group, benzyloxy group and a methylenedioxy group on the ring; with the proviso that when there are 2 or 3 substituents, they may be the same or different. The term "a 5 or 6 membered heterocyclic group" refers to a saturated or unsaturated 5 or 6 membered heterocyclic group which may contain one or more hetero atoms other than the nitrogen atom which is bonded to the quinolizine ring, such as a 1-pyrrolidinyl, piperidino, morpholino, 1-piperazinyl, 1-amidazolyl or 1-triazolyl group. The substituent or substituents attached to the 5 or 6 membered heterocyclic group defined above are selected from an alkyl group, phenyl group, a phenylalkyl group, a hydroxyalkyl group, a morpholinocarbonylalkyl group and a formyl group. In a preferred embodiment this invention provides a 4H-quinolizin-4-one compound of the formula: where R is an alkyl group or a phenylalkyl group; Ar is a substituted or unsubstituted phenyl group. In another preferred embodiment this invention provides a 4H-quinolizin-4-one compound of the formula: where R is an alkyl group or a phenylalkyl group; Het is a 5 or 6 membered heterocyclic group. The 4H-quinolizin-4-one derivative of the present invention selectively inhibit the formation of IgE. Pharmacological test data indicates that the 4H-quinolizin-4-one derivatives of formula (I) of the present invention have potential utility as drugs for diseases associated with IgE, such as allergic bronchial asthma, allergic rhinitis, atopic dermatitis and hypersensitiveness. The 4H-quinolizin-4-one compounds of formula (I) of the present invention may be prepared as follows: For example, of the 4H-quinolizin-4-one derivatives of formula (I), the 4H-quinolizin-4-one compounds corresponding to the formula (Ia): where R and Ar are as previously defined, may be prepared by the reaction of a compound corresponding to the formula: where R is as previously defined, with a compound corresponding to the formula: where R¹ is a group selected from a halogen atom, an alkyl group, an alkoxy group, an acyloxy group, nitro group, an acylamino group, an alkylthio group, phenyl group, benzoyl group, benzyloxy group and a methylenedioxy group; n is zero or an integer of 1-3; with the proviso that when n is 2 or 3, R¹ may be same or different, to prepare a compound corresponding to the formula: where R, R¹ and n are as previously defined, and the hydrolyzing the compound of formula (IV) above under acidic conditions, and if necessary, deacylating or reducting the obtained products. Of the 4H-quinolizin-4-one derivatives of formula (I) of the present invention, the 4H-quinolizin-4-one compounds corresponding to formula (Ib) may be prepared according to the method described by Kobayashi et al. in Yakugaku Zasshi vol. 89, No. 2, pp 203-208, 1969. That is a 4H-quinolizin-4-one derivative of the present invention corresponding to the formula: where R and Het are as previously defined, can be prepared by the reaction of a compound corresponding to the formula: where R is as previously defined, with a compound corresponding to the formula: to prepare a compound corresponding to the formula: where R is as previously defined, followed by the reaction of the compound of formula (VI) above with a heterocyclic compound corresponding to the formula: H-Het where Het is as previously defined. Compounds of formulae (II), (III) and (V) for use as starting materials can be prepared as follows: A compound of formula (II) can be prepared from 2-pyridylacetic acid according to the manner described in Compendium of Organic Synthetic Methods, Ed. by I.T. Harrison and S. Harrison, Wiley-Interscience New York, Vol. 1, pp 272-279 (1971). A compound of formula (III) can be prepared by the reaction of malononitrile, a substituted or unsubstituted benzoyl chloride and dimethyl sulfate in accordance with a procedure described in Chemische Berichte, Vol 91, pp 1830-1834, 1958. A compound of formula (V) can be prepared by the reaction of methyl cyanoacetate, carbon disulfide and a dimethyl sulfate in accordance with a procedure described in Chemische Berichte, Vol. 95, pp 2861-2870, 1962. The reaction of a compound of formula (II) with a compound of formula (III) can be conducted preferably in accordance with the following method. A compound of formula (II) is reacted with a compound of formula (III) in equal molar quantities, in the presence of a base such as sodium hydride or sodium alkoxide in inert organic solvent. And the reaction mixture is worked up to conventional procedures to obtain a 4-imino comopund of formula (IV). And then, the compound of formula (IV) above obtained is hydrolyzed under acidic conditions to obtain the 4H-quinolizin-4-one compound of formula (Ia). The reaction of a compound of formula (II) with a compound of formula (V) can be conducted in accordance with the following preferred method. A mixture of a compound of formula (II) and a compound of formula (V) in equal molar quantities is heated at 100-120°C for 2-10 hours, in the presence or absence of organic solvent, and then the reaction mixture is worked up to conventional procedures to obtain a compound of formula (VI). And then the compound of formula (VI) above obtained is reacted with a compound of formula (VII) in equal molar or excess quantities at a temperature between room temperature to 140°C for 2-48 hours, in the presence or absence of organic solvent, and the reaction mixture is worked up to conventional procedures to obtain the 4H-quinolizin-4-one compound of formula (Ib). The 4H-quinolizin-4-one derivatives represented by formula (I) of the present invention exhibit selective inhibitory activities on IgE formation. The inhibitory activities of the quinolizinone derivatives of formula (I) are confirmed by the determination of Igs produced in cultures of spleen cells from BALB/c mice which exhibit an adoptive secondary immune response against dinitrophenylated proteins of ascaris (DNP-As) according to a procedure described in Cellular Immunology, Vol. 58, pp 188-201, 1981. And the inhibitory activities of the quinolizinone derivative of formula (I) also are confirmed by the determination of serum concentrations of Igs in BALB/c mice which are immunized by DNP-As according to a procedure described in Immunology, Vol 21, pp 11-12, 1971. The results obtained by these tests demonstrate that the compounds of formula (I) of the present invention inhibit IgE formation, and minimally affect the production of Igs other than IgE. From the results obtained by these pharmacological tests, it can be expected that the compound of formula (I) of the present invention has properties suitable for application as a therapeutic agent for treatment of diseases associated with IgE in mannals. Furthermore, the compounds of the formula (I) of the present invention also selectively inhibit IgE production in cultures of peripheral blood lymphocytes from atopic patients. An acute toxicological test in mice shows that the compounds of formula (I) of the present invention have very low acute toxicity. The 4H-quinolizin-4-one derivatives of the general formula (I) of the present invention can be administered in various dosage forms depending upon the intended therapy. Typical dosage forms which can be used are tablets, pills, powder, liquid preparations, suspensions, emulsions, granules, capsules, suppositories, and injectable preparations. In molding the pharmaceutical compositions into a tablet form, a wide variety of conventional carriers known in the art can be used. Examples of suitable carriers are excipients such as glucose, lactose, starch, cacao butter, hardened vegetable oils, kaolin and talc; binders such as gum arabic powder, tragacanth powder, and ethanol; and disintegrants such a laminaria and agar. The tablets, if desired, can be coated and made into sugar-coated tablets, gelatin-coated tablets, film-coated tablets, or tablets coated with two or more layers. When a pharmaceutical composition is formulated into an injectable preparation, it is preferred that the resulting injectable solution and suspension are sterilized and rendered isotonic with respect to blood. In making the pharmaceutical composition into a solution or suspension, any diluents customarily used in the art can be employed. Examples of suitable diluents include water, ethyl alcohol, propylene glycol, polyoxyethylene sorbitol, and sorbitan esters. Sodium chloride, glucose or glycerol may be incorporated into a therapeutic agent in an amount sufficient to prepare an isotonic solution. The therapeutic agent may further contain ordinary dissolving aids, buffers, pain-alleviating agents, and preservatives, and optionally, coloring agents fragrances, flavors, sweeteners, and other pharmacologically active agents. The dosage of the quinolizinone derivatives of the present invention may be in a range between approximately 0.1 mg to 10 mg per kg by an oral administration, or between about 0.02 mg to 5 mg per kg by a parenteral administration per day in multiple doses depending upon the type of disease, the severity of condition to be treated, and the like. In another embodiment this invention provides a method for the treatment of diseases associated with IgE in a mammal which comprise administering an effective dosage of an IgE-formation-inhibiting 4H-quinolizin-4-one compound to the mammal. In further embodiment this invention provides a pharmaceutical composition for the treatment of diseases associated with IgE- in a mammal, which composition contain an effective dosage of an IgE-formation-inhibiting 4H-quinolizin-4-one compound. This invention is further illustrated in more detail by way of the following examples and pharmacological data. Example 1 3-Cyano-1-ethoxycarbonyl-2-phenyl-4H-quinolizin-4-one (S-1) A mixture of 2.50 g of ethyl 2-pyridylacetate and 2.79 g of 2-cyano-3-methoxy-3-phenylacrylonitrile was dissolved in 15 ml of dry N,N-dimethylformamide. To the solution was added 0.61 g of 60% sodium hydride and the reaction mixture was stirred for 1 hour at 60°C. The reaction mixture was poured into ice-water, and precipitated crystals were collected by filtration, washed with water and dried under vacume to obtain 2,50 g of 3-cyano-1-ethoxycarbonyl-4-imino-2-phenyl-4H-quinolizine. The imino compound obtained was dissolved in 50 ml of 90% acetic acid and the reaction mixture was heated under reflux for 72 hours. After completion of the reaction, the solvent was evaporated under reduced pressure. The residue was dissolved in dichloromethane and the solution was washed successively with 1N-hydrochloric acid, water and saturated sodium chloride solution and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure and the residue was recrystallized from methanol to obtain 2.13 g of 3-cyano-1-ethoxycarbonyl-2-phenyl-4H-quinolizin-4-one. Melting point: 175-176°C IR (KBr): 2210, 1715, 1665, 1625, 1600 cm⁻¹ ¹H NMR (CDCl₃): δ 0.77 (t, 3H), 3.92 (q, 2H), 7.36-7.52 (m, 6H), 7.84 (dt, 1H), 8.23 (d, 1H), 9.39 (d, 1H) Elementary analysis: C₁₉H₁₄N₂O₃ Example 2 The following compounds were obtained according to the same procedure as described in Example 1. 2-(4-Biphenylyl)-3-cyano-1-ethoxycarbonyl-4H-quinolizin-4-one (S-2) Melting point: 216-221°C IR (KBr): 2220, 1710, 1670, 1625 cm⁻¹ ¹H NMR (CDCl₃): δ 0.77 (t, 3H), 3.96 (q, 2H), 7.36-7.78 (m, 10H), 7.85 (dt, 1H), 8.25 (d, 1H), 9.40 (d, 1H) Elementary analysis: C₂₅H₁₈N₂O₃ 2-(4-Bromophenyl)-3-cyano-1-ethoxycarbonyl-4H-quinolizin-4-one (S-3) Melting point: 233-236°C IR (KBr): 2220, 1710, 1680, 1625 cm⁻¹ ¹H NMR (CDCl₃): δ 0.86 (t, 3H), 3.99 (q, 2H), 7.30 (d, 2H), 7.42 (t, 1H), 7.64 (d, 2H), 7.86 (dt, 1H), 8.26 (d, 1H), 9.40 (d, 1H) Elementary analysis: C₁₉H₁₃N₂O₃Br 3-Cyano-1-ethoxycarbonyl-2-(4-tert-butylphenyl)-4H-quinolizin-4-one (S-4) Melting point: 195-198°C IR (KBr): 2225, 1715, 1680, 1625 cm⁻¹ ¹H NMR (CDCl₃): δ 0.70 (t, 3H), 1.35 (s, 9H), 3.92 (q, 2H), 7.37 (d, 3H), 7,50 (d, 2H), 7.83 (dt, 1H), 8.21 (d, 1H), 9.38 (d, 1H) Elementary analysis: C₂₃H₂₂N₂O₃ 3-Cyano-2-(3,4-dimethoxyphenyl)-1-ethoxycarbonyl-4H-quinolizin-4-one (S-5) Melting point: 163-164°C IR (KBr): 2215, 1715, 1665, 1625 cm⁻¹ ¹H NMR (CDCl₃): δ 0.88 (t, 3H), 3,91 (s, 3H), 3.95 (s, 3H), 4.00 (q, 2H), 6.95-7.07 (m, 3H), 7.37 (t, 1H), 7.82 (dt, 1H), 8.16 (d, 1H), 9.37 (d, 1H) Elementary analysis: C₂₁H₁₈N₂O₅ 3-Cyano-1-ethoxycarbonyl-2-(4-methoxyphenyl)-4H-quinolizin-4-one (S-6) Melting point: 192-195°C IR (KBr): 2220, 1715, 1680, 1625, 1610 cm⁻¹ ¹H NMR (CDCl₃): δ 0.86 (t, 3H), 3.87 (s, 3H), 3.99 (q, 2H), 7.01 (d, 2H), 7.35 (d, 1H), 7.38 (d, 2H), 7.81 (dt, 1H), 8.16 (d, 1H), 9.37 (d, 1H) Elementary analysis: C₂₀H₁₆N₂O₄ 3-cyano-1-ethoxycarbonyl-2-(4-methylphenyl)-4H-quinolizin-4-one (S-7) Melting point: 185.5-186.5°C IR (KBr): 2220, 1700, 1675, 1625 cm⁻¹ ¹H NMR (CDCl₃): δ 0.80 (t, 3H), 2.42 (s, 3H), 3.96 (q, 2H), 7.26-7.40 (m, 5H), 7.82 (dt, 1H), 8.19 (d, 1H), 9.38 (d, 1H) Elementary analysis: C₂₀H₁₆N₂O₃ 3-Cyano-1-ethoxycarbonyl-2-(3,4-methylenedioxyphenyl)-4H-quinolizin-4-one (S-8) Melting point: 216-218°C IR (KBr): 2210, 1725, 1670, 1630 cm⁻¹ ¹H NMR (CDCl₃): δ 0.95 (t, 3H), 4.04 (q, 2H), 6.05 (s, 2H), 6.88- 6.92 (m, 3H), 7.37 (t, 1H), 7.83 (dt, 1H), 8.16 (d, 1H), 9.38 (d, 1H) Elementary analysis: C₂₀H₁₄N₂O₅ 3-Cyano-1-(2,4-dichlorophenyl)-1-ethoxycarbonyl-4H-quinolizin-4-one (S-9) Melting point: 187-188°C IR (KBr): 2210, 1720, 1680, 1625 cm⁻¹ ¹H NMR (CDCl₃): δ 0.90 (t, 3H), 3.95-4.10 (m, 2H), 7.21 (d, 1H), 7.38 (d, 1H), 7.47 (t, 1H), 7.55 (s, 1H), 7.91 (dt, 1H), 8.53 (d, 1H), 9.46 (d, 1H) Elementary analysis: C₁₉H₁₂N₂O₃Cl₂ 3-Cyano-2-phenyl-1-propoxycarbonyl-4H-quinolizin-4-one (S-10) Melting point: 156-158°C IR (KBr): 2210, 1700, 1670, 1620 cm⁻¹ ¹H NMR (CDCl₃): δ 0.64 (t, 3H), 1.17 (m, 2H), 3.82 (t, 2H), 7.38 (t, 1H), 7.40-7.51 (m, 5H), 7.83 (dt, 1H), 8.21 (d, 1H), 9.40 (d, 1H) Elementary analysis: C₂₀H₁₆N₂O₃ 3-Cyano-1-methoxycarbonyl-2-phenyl-4H-quinolizin-4-one (S-11) Melting point: 208-211°C IR (KBr): 2220, 1715, 1675, 1625 cm⁻¹ ¹H NMR (CDCl₃): δ 3.43 (s, 3H), 7.33-7.55 (m, 6H), 7.84 (dt, 1H), 8.19 (d, 1H), 9.39 (d, 1H) Elementary analysis: C₁₈H₁₂N₂O₃ 3-Cyano-1-ethoxycarbonyl-2-(4-fluorophenyl)-4H-quinolizin-4-one (S-12) Melting point: 209-214°C IR (KBr): 2220, 1705, 1665, 1625 cm⁻¹ ¹H NMR (CDCl₃): δ 0.86 (t, 3H), 3.98 (q, 2H), 7.19 (t, 2H), 7.36-7.46 (m, 3H), 7.86 (dt, 1H), 8.23 (d, 1H), 9.40 (d, 1H) Elementary analysis: C₁₉H₁₃N₂O₃F 3-Cyano-1-ethoxycarbonyl-2-(3-fluoro-4-methylphenyl)-4H-quinolizin-4-one (S-13) Melting point: 202-203.5°C IR (KBr): 2220, 1725, 1675, 1620 cm⁻¹ 1 H NMR (CDCl₃): δ 0.87 (t, 3H), 2.33 (brs, 3H), 4.00 (q, 2H), 7.05-7.13 (m, 2H), 7.30 (t, 1H), 7.40 (t, 1H), 7.85 (dt, 1H), 8.22 (d, 1H), 9.40 (d, 1H) Elementary analysis: C₂₀H₁₅N₂O₃F 3-Cyano-2-(3,4-dimethylphenyl)-1-ethoxycarbonyl-4H-quinolizin-4-one (S-14) Melting point: 160-163°C IR (KBr): 2210, 1715, 1675, 1625 cm⁻¹ ¹H NMR (CDCl₃): δ 0.81 (t, 3H), 2.31 (brs, 6H), 3.97 (q, 2H), 7.12-7.28 (m, 3H), 7.36 (t, 1H), 7.80 (dt, 1H), 8.17 (d, 1H), 9.37 (d, 1H) Elementary analysis: C₂₁H₁₈N₂O₃ 3-Cyano-1-ethoxycarbonyl-2-(4-ethoxyphenyl)-4H-quinolizin-4-one (S-15) Melting point: 164-166°C IR (KBr): 2210, 1705, 1675, 1625, 1605 cm⁻¹ ¹H NMR (CDCl₃): δ 0.87 (t, 3H), 1.44 (t, 3H), 3.99 (q, 2H), 4.10 (q, 2H), 6.99 (d, 2H0, 7.34 (t, 1H), 7.37 (d, 2H), 7.80 (dt, 1H), 8.16 (dt, 1H), 9.37 (d, 1H) Elementary analysis: C₂₁H₁₈N₂O₄ 3-Cyano-1-ethoxycarbonyl-2-(4-isopropoxyphenyl)-4H-quinolizin-4-one (S-16) Melting point: 168-169°C IR (KBr): 2210, 1710, 1670, 1630, 1605 cm⁻¹ ¹H NMR (CDCl₃): δ 0.86 (t, 3H), 1.38 (d, 6H), 3.99 (q, 2H), 4.63 (m, 1H), 6.98 (d, 2H), 7.31-7.39 (m, 3H), 7.80 (dt, 1H), 8.17 (d, 1H), 9.37 (d, 1H) Elementary analysis: C₂₂H₂₀N₂O₄ 3-Cyano-1-ethoxycarbonyl-2-(3-methoxyphenyl)-4H-quinolizin-4-one (S-17) Melting point: 150.5-151.5°C IR (KBr): 2220, 1710, 1670, 1620 cm⁻¹ ¹H NMR (CDCl₃): δ 0.83 (t, 3H), 3.85 (s, 3H), 3.97 (q, 2H), 6.94-7.05 (m, 3H), 7.36-7.42 (m, 2H), 7.84 (dt, 1H), 8.22 (d, 1H), 9.39 (d, 1H) Elementary analysis: C₂₀H₁₆N₂O₄ 2-(4-Benzyloxyphenyl)-3-cyano-1-ethoxycarbonyl-4H-quinolizin-4-one (S-18) Melting point: 185-187.5°C IR (KBr): 2220, 1705, 1670, 1625, 1610 cm⁻¹ ¹H NMR (CDCl₃): δ 0.83 (t, 3H), 3.97 (q, 2H), 5.13 (s, 2H), 7.08 (d, 2H), 7.31-7.48 (m, 8H), 7.81 (dt, 1H), 8.17 (d, 1H), 9.38 (d, 1H) Elementary analysis: C₂₆H₂₀N₂O₄ 3-Cyano-1-ethoxycarbonyl-2-(3,4,5-trimethoxyphenyl)-4H-quinolizin-4-one (S-19) Melting point: 223.5-225°C IR (KBr): 2220, 1720, 1680, 1630 cm⁻¹ ¹H NMR (CDCl₃): δ 0.89 (t, 3H), 3.89 (brs, 6H), 3.92 (s, 3H), 4.00 (q, 2H), 6.67 (brs, 2H), 7.38 (t, 1H), 7.84 (dt, 1H), 8.17 (d, 1H), 9.38 (d, 1H) Elementary analysis: C₂₂H₂₀N₂O₆ 3-Cyano-1-ethoxycarbonyl-2-(4-nitrophenyl)-4H-quinolizin-4-one (S-20) Melting point: 211-214°C IR (KBr): 2210, 1710, 1680, 1625 cm⁻¹ ¹H NMR (CDCl₃): δ 0.83 (t, 3H), 3.97 (q, 2H), 7.48 (t, 1H), 7.06 (d, 2H), 7.93 (dt, 1H), 8.38 (m, 3H), 9.46 (d, 1H) Elementary analysis: C₁₉H₁₃N₃O₅ 3-Cyano-1-ethoxycarbonyl-2-(2-methoxyphenyl)-4H-quinolizin-4-one (S-21) Melting point: 213.5-214°C IR (KBr): 2220, 1715, 1680, 1625 cm⁻¹ ¹H NMR (CDCl₃): δ 0.80 (t, 3H), 3.85 (brs, 3H),3.96 (q, 2H), 7.00-7.10 (m, 2H), 7.20 (d, 1H), 7.37 (t, 1H), 7.44 (t, 1H), 7.82 (dt, 1H), 8.35 (d, 1H), 9.39 (d, 1H) Elementary analysis: C₂₀H₁₆N₂O₄ 2-(3-Bromophenyl)-3-cyano-1-ethoxycarbonyl-4H-quinolizin-4-one (S-22) Melting point: 180-182.5°C IR (KBr): 2220, 1700, 1680, 1625 cm⁻¹ ¹H NMR (CDCl₃): δ 0.88 (t, 3H), 4.00 (q, 2H), 7.37-7.47 (m, 3H), 7.54 (brs, 1H), 7.62 (m, 1H), 7.87 (dt, 1H), 8.29 (d, 1H), 9.42 (d, 1H) Elementary analysis: C₁₉H₁₃N₂O₃Br 2-(3-Benzyloxy-4-methoxyphenyl)-3-cyano-1-ethoxycarbonyl-4H-quinolizin-4-one (S-23) Melting point: 160-160.5°C IR (KBr): 2210, 1705, 1680, 1625 cm⁻¹ ¹H NMR (CDCl₃): δ 0.82 (t, 3H), 3.89 (q, 2H), 3.94 (s, 3H), 5.17 (brs, 2H), 6.97-7.07 (m, 3H), 7.30-7.41 (m, 4H), 7.46 (d, 2H), 7.80 (dt, 1H), 8.15 (d, 1H), 9.37 (d, 1H) Elementary analysis: C₂₇H₂₂N₂O₅ 2-(4-Benzyloxy-3-methoxyphenyl)-3-cyano-1-ethoxycarbonyl-4H-quinolizin-4-one (S-24) Melting point: 170-171.5°C IR (KBr): 2220, 1710, 1665, 1625 cm⁻¹ ¹H NMR (CDCl₃): δ 0.80 (t, 3H), 3.91 (s, 3H), 3.92 (q, 2H), 5.21 (brs, 2H), 6.90-7.00 (m, 3H), 7.30-7.48 (m, 6H), 7.80 (dt, 1H), 8.14 (d, 1H), 9.36 (d, 1H) Elementary analysis: C₂₇H₂₂N₂O₅ 3-Cyano-1-ethoxycarbonyl-2-(4-methylthiophenyl)-4H-quinolizin-4-one (S-25) Melting point: 191-193°C IR (KBr): 2205, 1700, 1665, 1620 cm⁻¹ ¹H NMR (CDCl₃): δ 0.85 (t, 3H), 2.54 (s, 3H), 3.97 (q, 2H), 7.34 (brs, 4H), 7.37 (t, 1H), 7.83 (t, 1H), 8.21 (d, 1H), 9.39 (d, 1H) Elementary analysis: C₂₀H₁₆N₂O₃S 2-(4-Acetylaminophenyl)-3-cyano-1-ethoxycarbonyl-4H-quinolizin-4-one (S-26) Melting point: 292-296°C IR (KBr): 2215, 1720, 1700, 1650, 1620 cm⁻¹ ¹H NMR (DMSO-d₆): δ 1.36 (t, 3H), 2.63 (s, 3H), 4.50 (q, 2H), 7.87 (d, 2H), 8.17 (m, 1H), 8.26 (d, 2H), 8.57-8.70 (m, 2H), 9.81 (d, 1H), 10.70 (brs, 1H) Elementary analysis: C₂₁H₁₇N₃O₄ 2-(4-Benzoylphenyl)-3-cyano-1-ethoxycarbonyl-4H-quinolizin-4-one (S-27) Melting point: 226-228°C IR (KBr): 2210, 1710, 1660, 1625 cm⁻¹ ¹H NMR (CDCl₃): δ 0.83 (t, 3H), 3.98 (q, 2H), 7.41-7.68 (m, 6H), 7.82-7.98 (m, 5H), 8.33 (d, 1H), 9.44 (d, 1H) Elementary analysis: C₂₆H₁₈N₂O₄ 3-Cyano-2-(2,3-dimethoxyphenyl)-1-ethoxycarbonyl-4H-quinolizin-4-one (S-28) Melting point: 147-148°C IR (KBr): 2225, 1710, 1670, 1620 cm⁻¹ ¹H NMR (CDCl₃): δ 0.84 (t, 3H), 3.86 (s, 3H), 3.92 (s, 3H), 3.99 (q, 2H), 6.77 (d, 1H), 7.04 (d, 1H), 7.12 (m, 1H), 7.39 (t, 1H), 7.82 (dt, 1H), 8.36 (d, 1H), 9.41 (d, 1H) Elementary analysis: C₂₁H₁₈N₂O₅ 3-Cyano-2-(3,5-dimethoxyphenyl)-ethoxycarbonyl-4H-quinolizin-4-one (S-29) Melting point: 175.5-177°C IR (KBr): 2245, 1720, 1680, 1630 cm⁻¹ ¹H NMR (CDCl₃): δ 0.89 (t, 3H), 3.81 (brs, 6H), 4.02 (q, 2H), 6.56 (brs, 3H), 7.38 (t, 1H), 7.84 (dt, 1H), 8.20 (d, 1H), 9.39 (d, 1H) Elementary analysis: C₂₁H₁₈N₂O₅ Example 3 3-Cyano-1-ethoxycarbonyl-2-(4-hydroxyphenyl)-4H-quinolizin-4-one (S-30) A mixture of 165 mg of ethyl 2-pyridylacetate and 242 mg of 3-(4-acetoxyphenyl)-2-cyano-3-methoxyacrylonitrile was dissolved in 1 ml of dry N,N-dimethylformamide. To the solution was added 40 mg of 60% sodium hydride at room temperature and the reaction mixture was stirred for 1 hour at 60°C. The reaction mixture was poured into ice-water, and precipitated crystals were collected by filtration, washed with water and dried to obtain 120 mg of 2-(4-acetoxyphenyl)-3-cyano-1-ethoxycarbonyl-4-imino-4H-quinolizine. The obtained imine compound was added to 5 ml of 90% acetic acid and the reaction mixture was heated under reflux for 72 hours. After complextion of the reaction, the solvent was evaporated under reduced pressure. The residue was dissolved in dichloromethane, and the solution was washed successively with 1N-hydrochloric acid, water and saturated sodium chloride solution and dried over anhydrous sodium sulfate. The solvent was evaporated and the residue was recrystallized from methanol to obtain 75 mg of 3-cyano-1-ethoxycarbonyl-2-(4-hydroxyphenyl)-4H-quinolizin-4-one. Melting point: 284-290°C IR (KBr): 3250, 2220, 1720, 1640, 1620, 1610 cm⁻¹ ¹H NMR (DMSO-d₆): δ 0.97 (t, 3H), 4.10 (q, 2H), 7.02 (d, 2H), 7,34 (d, 2H), 7.73 (dt, 1H), 8.15-8.25 (m, 2H), 9.37 (d, 1H), 10.02 (brs, 1H) Elementary analysis: C₁₉H₁₄N₂O₄ Example 4 The following compounds were obtained according to the same procedure as described in Example 3. 3-Cyano-2-(3,4-dihydroxyphenyl)-1-ethoxycarbonyl-4H-quinolizin-4-one (S-31) Melting point: 285-287°C IR (KBr): 3400, 3250, 2220, 1720, 1665, 1625 cm⁻¹ ¹H NMR (DMSO-d₆): δ 1.00 (t, 3H), 4.12 (q, 2H), 6.88 (dd, 1H), 6.90-7.11 (m, 2H), 7.72 (dt, 1H), 8.11-8.24 (m, 2H), 9.36 (d, 1H), 9.42 (brs, 1H), 9.48 (brs, 1H) Elementary analysis: ₁₉H₁₄N₂O₅ 3-Cyano-1-ethoxycarbonyl-2(4-hydroxy-3-methoxyphenyl)-4H-quinolizin-4-one (S-32) Melting point: 190-193°C IR (KBr): 3400, 2220, 1715, 1670, 1625 cm⁻¹ ¹H NMR (DMSO-d₆): δ 0.99 (t, 3H), 3.89 (s, 3H), 4.13 (q, 2H), 6.93-7.10 (m, 3H), 7.73 (dt, 1H), 8.15-8.28 (m, 2H), 9.37 (d, 1H), 9.64 (brs, 1H) Elementary analysis: C₂₀H₁₆N₂O₅ 3-Cyano-1-ethoxycarbonyl-2-(3-hydroxy-4-methoxyphenyl)-4H-quinolizin-4-one (S-33) Melting point: 220-222°C IR (KBr): 3375, 2220, 1710, 1655, 1625 cm⁻¹ ¹H NMR (DMSO-d₆): δ 0.91 (t, 3H), 3.96 (s, 3H), 4.02 (q, 2H), 5.68 (brs, 1H), 6.91-7.02 (m, 3H), 7.34 (t, 1H), 7.79 (dt, 1H), 8.14 (d,1H), 9.36 (d, 1H) Elementary analysis: C₂₀H₁₆N₂O₅ Example 5 2-(4-Aminophenyl)-3-cyano-1-ethoxycarbonyl-4H-quinolizin-4-one (S-34) To a stirred solution of 100 mg of 3-cyano-1-ethoxycarbonyl-2-(4-nitrophenyl)-4H-quinolizin-4-one (S-20) in 10 ml of ethanol and 5 ml of acetone was added dropwise a solution of 240 mg of sodium hydrosulfite in 5 ml of water during 10 minutes. The reaction mixture was heated under reflux for 1 hour and poured into ice-water. The solution was extracted with dichloromethane and the organic layer was dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure and the residue was recrystallized from methanol to obtain 40 mg of 2-(4-aminophenyl)-3-cyano-1-ethoxycarbonyl-4H-quinolizin-4-one. Melting point: 260-262°C IR (KBr): 3450, 3350, 2210, 1720, 1660, 1630, 1605 cm⁻¹ ¹H NMR (DMSO-d₆): δ 1.03 (t, 3H), 4.15 (q, 2H), 5.71 (br, 2H), 6.78 (d, 2H), 7.21 (d, 2H), 7.67 (dt, 1H), 8.06-8.19 (m, 2H), 9.34 (d, 1H) Elementary analysis: C₁₉H₁₅N₃O₃ Reference Example 1 3-Cyano-1-ethoxycarbonyl-2-methylthio-4H-quinolizin-4-one (R-1) A mixture of 1.42 g of ethyl 2-pyridylacetate and 1.75 g of methyl 2-cyano-3,3-bismethylthioacrylate was heated at 120°C for 10 hours. To the reaction mixture was added 8 ml of methanol, the precipitated crystals were collected by filtration and recrystallized from methanol to obtain 1.19 g of 3-cyano-1-ethoxycarbonyl-2-methylthio-4H-quinolizin-4-one as pale yellow crystals. Melting point: 128-129°C IR (KBr): 2200, 1695, 1665 cm⁻¹ ¹H NMR (CDCl₃): δ 1.44 (t, 3H), 2.76 (s, 3H), 4.48 (q, 2H), 7.30 (m, 1H), 7.80 (m, 2H), 9.27 (d, 1H) Elementary analysis: C₁₄H₁₂N₂O₃S Reference Example 2 The following compound was obtained according to the same procedure as described in Reference Example 1. 3-Cyano-2-methylthio-1-(3-phenylpropoxycarbonyl)-4H-quinolizin-4-one (R-2) Melting point: 80-81°C IR (KBr): 2200, 1700, 1665, 1620 cm⁻¹ ¹H NMR (CDCl₃): δ 2.13 (m, 2H), 2.75 (s, 3H), 2.78 (t, 2H), 4.43 (t, 2H), 7.18-7.36 (m, 6H), 7.77 (m, 2H), 9.26 (d, 1H) Elementary analysis: C₂₁H₁₈N₂O₃S Example 6 3-Cyano-1-ethoxycarbonyl-2-piperidino-4H-quinolizin-4-one (S-35) A mixture of 1.44 g of 3-cyano-1-ethoxycarbonyl- 2-methylthio-4H-quinolizin-4-one and 5.0 ml of piperidine in 10 ml of acetonitrile was heated under reflux for 10 hours. The reaction mixture was concentrated under reduced pressure and the residue was chromatographed on a silica gel column using a mixed solvent of ethyl acetate and n-hexane (2: 1) as an eluent to obtain 0.95 g of 3-cyano-1-ethoxycarbonyl-2-piperidino-4H-quinolizin-4-one. Melting point: 143-144°C IR (KBr): 2200, 1710, 1665, 1630 cm⁻¹ ¹H NMR (CDCl₃): δ 1.38 (t, 3H), 1.60-1.82 (m, 6H), 3.33-3.46 (m, 4H), 4.39 (q, 2H), 6.99 (t, 1H), 7.53 (dt, 1H), 7.95 (d, 1H), 9.06 (d, 1H) Elementary analysis: C₁₈H₁₉N₃O₃ Example 7 The following compounds were obtained according to the same procedure as described in Example 6. 3-Cyano-1-(3-phenylpropoxycarbonyl)-2-piperidino-4H-quinolizin-4-one (S-36) Melting point: 97-98°C IR (KBr): 2200, 1710, 1665, 1630 cm⁻¹ ¹H NMR (CDCl₃): δ 1.57-1.82 (m, 6H), 2.09 (m, 2H), 2.75 (t, 2H), 3.42 (m, 4H), 4.34 (t, 2H), 7.00 (t, 1H), 7.14-7.34 (m, 5H), 7.53 (dt, 1H), 7.93 (d, 1H), 9.08 (d, 1H) Elementary analysis: C₂₅H₂₅N₃O₃ 3-Cyano-1-ethoxycarbonyl-2-(1-pyrrolidinyl)-4H-quinolizin-4-one (S-37) Melting point: 171-172°C IR (KBr): 2200, 1700, 1650, 1620 cm⁻¹ ¹H NMR (CDCl₃): δ 1.40 (t, 3H), 1.99 (m, 4H), 3.81 (m, 4H), 4,38 (q, 2H), 6.82 (t, 1H), 7.40 (dt, 1H), 7.65 (d, 1H), 8.93 (d, 1H) Elementary analysis: C₁₇H₁₇N₃O₃ 3-Cyano-1-(3-phenylpropoxycarbonyl)-2-)(1-pyrrolidinyl)-4H-quinolizin-4-one (S-38) Melting point: 136-137°C IR (KBr): 2210, 1695, 1650, 1620 cm⁻¹ ¹H NMR (CDCl₃): δ 1.97 (m, 4H), 2.08 (m, 2H), 2.74 (t, 2H), 3.80 (m, 4H), 4.32 (t, 2H), 6.83 (t, 1H), 7.16-7.43 (m, 6H), 7.63 (d, 1H), 8.93 (d, 1H) Elementary analysis: C₂₄H₂₃N₃O₃ 3-Cyano-1-ethoxycarbonyl-2-[4-(2-hydroxyethyl)piperazin-1-yl]-4H-quinolizin-4-one (S-39) Melting point: 159-161°C IR (KBr): 2220, 1710, 1670, 1630 cm⁻¹ ¹H NMR (CDCl₃): δ 1.33 (t, 3H), 1.75 (br, 1H), 2.68 (t, 2H), 2.77 (br, 4H), 3.54 (br, 4H), 3.68 (t, 2H), 4.43 (q, 2H), 7.06 (d, 1H), 7,60 (dt, 1H), 7.99 (d, 1H), 9.12 (d, 1H) Elementary analysis: C₁₉H₂₂N₄O₄ 3-Cyano-1-ethoxycarbonyl-2-(4-formylpiperazin-1-yl)-4H-quinolizin-4-one (S-40) Melting point: 235-238°C IR (KBr): 2220, 1700, 1665, 1655, 1630 cm⁻¹ ¹H NMR (CDCl₃): δ 1.41 (t, 3H), 3.37 (t, 2H), 3.54 (m, 2H), 3.65 (m, 2H), 3.79 (t, 2H), 4.43 (q, 2H), 7.16 (d, 1H), 7,68 (dt, 1H), 8.06 (d, 1H), 8.15 (brs, 1H), 9.18 (d, 1H) Elementary analysis: C₁₈H₁₈N₄O₄ 3-Cyano-2-(4-formylpiperazin-1-yl)-1-(3-phenylpropoxycarbonyl)-4H-quinolizin-4-one (S-41) Melting point: 100-104°C IR (KBr): 2210, 1705, 1665, 1630 cm⁻¹ ¹H NMR (CDCl₃): δ 2.09 (m, 2H), 2.74 (t, 2H), 3.35 (t, 2H), 3.50 (m, 2H), 3.61 (m, 2H), 3.75 (m, 2H), 4.36 (t, 2H), 7.13-7.32 (m, 6H), 7.69 (dt, 1H), 8.00 (d, 1H), 8.13 (brs, 1H), 9.19 (d, 1H) Elementary analysis: C₂₅H₂₄N₄O₄ 3-Cyano-1-ethoxycarbonyl-2-(4-methylpiperazin-1-yl)-4H-quinolizin-4-one (S-42) Melting point: 187-188°C IR (KBr): 2210, 1710, 1660, 1630 cm⁻¹ ¹H NMR (CDCl₃): δ 1.40 (t, 3H), 2.39 (brs, 3H), 2.65 (br, 4H), 3.54 (br, 4H), 4.40 (q, 2H), 7.05 (t, 1H), 7.59 (dt, 1H), 8.00 (d, 1H), 9.11 (d, 1H) Elementary analysis: C₁₈H₂₀N₄O₃ 3-Cyano-2-(4-methylpiperazin-1-yl)-1-(3-phenylpropoxycarbonyl)-4H-quinolizin-4-one (S-43) Melting point: 118-120°C IR (KBr): 2210, 1710, 1670, 1630 cm⁻¹ ¹H NMR (CDCl₃): δ 2.10 (m, 2H), 2.39 (brs, 3H), 2.67 (br, 4H), 2.73 (t, 2H), 3.54 (br, 4H), 4.37 (t, 2H), 7.07 (t, 1H), 7.13-7.30 (m, 5H), 7.59 (dt, 1H), 7.98 (d, 1H), 9.12 (d, 1H) Elementary analysis: C₂₅H₂₆N₄O₃ 2-(4-Benzylpiperidino)-3-cyano-1-ethoxycarbonyl-4H-quinolizin-4-one (S-44) Melting point: 168-170°C IR (KBr): 2205, 1705, 1665, 1625 cm⁻¹ ¹H NMR (CDCl₃): δ 1.38 (t, 3H), 1.47-1.82 (m, 5H), 2.62 (d, 2H), 3.02 (t, 2H), 3.80 (d, 2H), 4.37 (q, 2H), 6.99 (t, 1H), 7.14-7.33 (m, 5H), 7.54 (dt, 1H), 7.95 (d, 1H), 9.08 (d, 1H) Elementary analysis: C₂₅H₂₅N₃O₃ 2-(4-Benzylpiperidino)-3-cyano-1-(3-phenylpropoxycarbonyl)-4H-quinolizin-4-one (S-45) Melting point: 169-171°C IR (KBr): 2210, 1705, 1670, 1630 cm⁻¹ ¹H NMR (CDCl₃): δ 1.45-1.80 (m, 5H), 2.07 (m, 2H), 2.60 (d, 2H), 2.73 (t, 2H), 3.03 (t, 2H), 3.79 (d, 2H), 4.31 (t, 2H), 7.01 (t, 1H), 7.12-7.33 (m, 10H), 7.55 (dt, 1H), 7.91 (d, 1H), 9.10 (d, 1H) Elementary analysis: C₃₂H₃₁N₃O₃ 3-Cyano-1-ethoxycarbonyl-2-(4-phenylpiperidino)-4H-quinolizin-4-one (S-46) Melting point: 162-164°C IR (KBr): 2210, 1700, 1670, 1630 cm⁻¹ ¹H NMR (CDCl₃): δ 1.46 (t, 3H), 1.90-2.11 (m, 4H), 2.87 (m, 1H), 3.25 (dt, 2H), 3.94 (d, 2H), 4.44 (q, 2H), 7.03 (t, 1H), 7.19-7.38 (m, 5H), 7.58 (dt, 1H), 7.98 (d, 1H), 9.11 (d, 1H) Elementary analysis: C₂₄H₂₃N₃O₃ 3-Cyano-2-(4-phenylpiperidino)-1-(3-phenylpropoxycarbonyl)-4H-quinolizin-4-one (S-47) Amorphous solid IR (KBr): 2210, 1710, 1665, 1630 cm⁻¹ ¹H NMR (CDCl₃): δ 1.91-2.19 (m, 6H), 2.69-2.82 (m, 3H), 3.23 (dt, 2H), 3.93 (d, 2H), 4.39 (t, 2H), 7.05 (t, 1H), 7.17-7.38 (m, 10H), 7.69 (dt, 1H), 7.96 (d, 1H), 9.13 (d, 1H) Elementary analysis: C₃₁H₂₉N₃O₃ 3-Cyano-1-ethoxycarbonyl-2-morpholino-4H-quinolizin-4-one (S-48) Melting point: 205-206°C IR (KBr): 2220, 1710, 1660, 1625 cm⁻¹ ¹H NMR (CDCl₃): δ 1.43 (t, 3H), 3.49 (t, 3H), 3.88 (t, 4H), 4.43 (q, 2H), 7.08 (t, 1H), 7.63 (dt, 1H), 8.00 (d, 1H), 9.14 (d, 1H) Elementary analysis: C₁₇H₁₇N₃O₄ 3-Cyano-2-morpholino-1-(3-phenylpropoxycarbonyl)-4H-quinolizin-4-one (S-49) Melting point: 112-113°C IR (KBr): 2225, 1705, 1670, 1630 cm⁻¹ ¹H NMR (CDCl₃): δ 2.11 (m, 2H), 2.75 (t, 2H), 3.48 (t, 4H), 3.88 (t, 4H), 4.39 (t, 2H), 7.09 (t, 1H), 7.15-7.33 (m, 5H), 7.61 (dt, 1H), 7.96 (d, 1H), 9.15 (d, 1H) Elementary analysis: C₂₄H₂₃N₃O₄ 3-Cyano-1-ethoxycarbonyl-2-(imidazol-1-yl)-4H-quinolizin-4-one (S-50) Melting point: 141-142°C IR (KBr): 2230, 1715, 1685, 1620 cm⁻¹ ¹H NMR (CDCl₃): δ 1.06 (t, 3H), 4.09 (q, 2H), 7.27 (brs, 1H), 7.29 (brs, 1H), 7.54 (t, 1H), 7.79 (brs, 1H), 8.00 (dt, 1H), 8.43 (d, 1H), 9.46 (d, 1H) Elementary analysis: C₁₆H₁₂N₄O₃ 3-Cyano-2-(imidazol-1-yl)-1-(3-phenylpropoxycarbonyl)-4H-quinolizin-4-one (S-51) Melting point: 123-129°C IR (KBr): 2220, 1720, 1680, 1620 cm⁻¹ ¹H NMR (CDCl₃): δ 1.20 (m, 2H), 2.50 (t, 2H), 4.06 (t, 2H), 7.07-7.30 (m, 7H), 7.55 (t, 1H), 7.80 (brs, 1H), 8.00 (dt, 1H), 8.40 (d, 1H), 9.46 (d, 1H) Elementary analysis: C₂₃H₁₈N₄O₃ 3-Cyano-1-ethoxycarbonyl-2-(1,3,4-triazol-1-yl)-4H-quinolizin-4-one (S-52) Melting point: 164.5-165.5°C IR (KBr): 2220, 1715, 1690, 1620 cm⁻¹ ¹H NMR (CDCl₃): δ 1.05 (t, 3H), 4.13 (q, 2H), 7.55 (t, 1H), 8.00 (t, 1H), 8.20 (s, 1H), 8.50 (d, 1H), 8.76 (s, 1H), 9.47 (d, 1H) Elementary analysis: C₁₅H₁₁N₅O₃ 3-Cyano-1-(3-phenylpropoxycarbonyl)-2-(1,3,4-triazol-1-yl)-4H-quinolizin-4-one (S-53) Melting point: 159-160°C IR (KBr): 2210, 1720, 1680, 1620 cm⁻¹ ¹H NMR (CDCl₃): δ 1.74 (m, 2H), 2.52 (t, 2H), 4.10 (t, 2H), 7.07-7.31 (m, 5H), 7.54 (t, 1H), 8.00 (dt, 1H), 8.16 (s, 1H), 8.46 (d, 1H), 8.76 (s, 1H), 9.47 (d, 1H) Elementary analysis: C₂₂H₁₇N₅O₃ 3-Cyano-2-[4-(2-hydroxyethyl)piperazin-1-yl]-1-(3-phenylpropoxycarbonyl)-4H-quinolizin-4-one (S-54) Melting point: 138-141°C IR (KBr): 2210, 1710, 1675, 1625 cm⁻¹ ¹H NMR (CDCl₃): δ 1.62 (br, 1H), 2.12 (m, 2H), 2.64-2.81 (m, 8H), 3.55 (br, 4H), 3.79 (br, 2H), 4.39 (t, 2H), 7.08 (t, 1H), 7.17-7.32 (m, 5H), 7.62 (dt, 1H), 7.97 (d, 1H), 9.13 (d, 1H) Elementary analysis: C₂₆H₂₈N₄O₄ 3-Cyano-1-ethoxycarbonyl-2-(4-morpholinocarbonylmethylpiperazin-1-yl)-4H-quinolizin-4-one (S-55) Melting point: 178-179°C IR (KBr): 2210, 1695, 1670, 1625 cm⁻¹ ¹H NMR (CDCl₃): δ 1.43 (t, 3H), 2.70-3.76 (m, 18H), 4.46 (q, 2H), 7.10 (t, 1H), 7.74 (t, 1H), 8.04 (d, 1H), 9.15 (d, 1H) Elementary analysis: C₂₃H₂₇N₅O₅ 3-Cyano-2-(4-morpholinocarbonylmethylpiperazin-1-yl)-1-(3-phenylpropoxycarbonyl)-4H-quinolzin-4-one (S-56) Melting point: 198-200°C IR (KBr): 2210, 1695, 1675, 1525 cm⁻¹ ¹H NMR (CDCl₃): δ 2.11 (m, 2H), 2.75 (t, 2H), 3.25-3.73 (m, 18H), 4.41 (t, 2H), 7.09 (t, 1H), 7.14-7.31 (m, 5H), 7.62 (t, 1H), 8.08 (d, 1H), 9.14 (d, 1H) Elementary analysis: C₃₀H₃₃N₅O₅ Example 8 3-Cyano-1-(2-hydroxyethyloxycarbonyl)-2-piperidino-4H-quinolizin-4-one (S-57) To a solution of 1.10 g of 3-cyano-1-ethoxycarbonyl-2-piperidino-4H-quinolizin-4-one (Example 6, S-35) in 30 ml of ethylene glycol was added 150 mg of 60% sodium hydride, and the reaction mixture was stirred at 100°C for 14 hours. After cooling, the precipitated crystals were collected by filtration and then the crude crystals were chromatographed on a silica gel column using a mixed solvent of dichloromethane and diethyl ether (1: 1) as an eluent to obtain 180 mg of 3-cyano-1-(2-hydroxyethoxycarbonyl)-2-piperidino-4H-quinolizin-4-one. Melting point: 140-141°C IR (KBr): 3375, 2210, 1710, 1675, 1640, 1630 cm⁻¹ ¹H NMR (CDCl₃): δ 1.62-1.82 (m, 7H), 3.47 (m, 4H), 3.99 (m, 2H), 4.47 (m, 2H), 7.00 (t, 1H), 7.55 (dt, 1H), 8.02 (d, 1H), 9.07 (d, 1H) Elementary analysis: C₁₈H₁₉N₃O₄ Test Example Determination of Igs produced in in vitro culture BALB/c mice were immunized intraperitoneally with 5 µg of DNP/As adsorbed on 4 mg aluminum hydroxide gel. Four weeks after the immunization, the spleens were excised from the mice and 5 × 10⁷ spleen cells were transferred intravenously into the recipient mice which had been exposed to 600 rad of X-ray irradiation. Immediately after cell transfer, the recipients were then immunized intraperitoneally with 5 µg of DNP-As adsorbed on 4 mg aluminum hydroxide gel to induce adoptive secondary immune response. Further 4 weeks after the immunization of recipients, the spleens were excised from them and the spleen cell suspensions containing 5 × 10⁶ cells/ml were cultured with or without a compound to be tested in 96-well micro-titer plates at 37°C for 4 days. IgE and IgG secreted into the culture supernatant was each determined correspondingly by ELISA and the inhibitory effect was calculated according to the following equation. The results obtained were shown below:

Claims: 1. A 4H-quinolizin-4-one derivative of the general formula: where R is an alkyl group or a phenylalkyl group; A is a substituted or unsubstituted phenyl group or a substituted or unsubstituted 5 or 6 membered heterocyclic group which is bonded to the quinolizine ring at the nitrogen atom of the heterocyclic ring; and wherein the terms "alkyl" and the "alkyl" moiety in "phenyl-alkyl", "hydroxyalkyl", "alkylthio" and "morpholino-carbonylalkyl" refer to a straight or branched alkyl group having 1 to 6 carbon atoms; and the term "a 5 or 6 membered heterocyclic group" refers to a saturated or unsaturated 5 or 6 membered heterocyclic group which may contain one or more hetero atoms other than the nitrogen atom which is bonded to the quinolizine ring, such as a 1-pyrrolidinyl, piperidino, morpholino, 1-piperazinyl, 1-amidazolyl or 1-triazolyl group, and the substituent or substituents attached to the 5 or 6 membered heterocyclic group as defined above are selected from an alkyl group, phenyl group, a phenylalkyl group, a hydroxyalkyl group, a morpholino-carbonylalkyl group and a formyl group; and the term "a substituted or unsubstituted phenyl group" refers to a substituted or unsubstituted phenyl group which may have 1 to 3 substituents selected from a halogen atom, an alkyl group, an alkoxy group, hydroxy group, nitro group, amino group, an acylamino group, an alkylthio group, phenyl group, benzoyl group, benzyloxy group and a methylenedioxy group on the ring; with the proviso that when there are 2 or 3 substituents, they may be the same or different, wherein the term "alkoxy" refers to a straight or branched alkoxy group having 1 to 6 carbon atoms. 2. A 4H-quinolizin-4-one compound of the formula where R is an alkyl group or a phenylalkyl group; Ar is a substituted or unsubstituted phenyl group; and wherein "alkyl" and "phenylalkyl", and the term "a substituted or unsubstituted pheny group" are as defined in claim 1. 3. A 4H-quinolizin-4-one compound of the formula: where R is an alkyl group or a phenylalkyl group, as defined in claim 1; Het is a 5 or 6 membered heterocyclic group, as defined in claim 1. 4. A pharmaceutical composition for the treatment of allergic bronchial asthma, allergic rhinitis, atopic dermatitis and hypersensitive diseases associated with immunoglobulin E in a mammal, which composition contains an immunoglobulin E-formation-inhibiting 4H-quinolizin-4-one compound, or a pharmaceutically acceptable salt thereof, together with an inert diluent or carrier. 5. A pharmaceutical composition as claimed in claim 4 wherein the 4H-quinolizin-4-one compound is a compound as claimed in any of claims 1 to 3, or a pharmaceutically acceptable salt thereof. 6. 4H-quinolizin-4-one derivatives being 3-Cyano-1-ethoxycarbonyl-2-phenyl-4H-quinolizin-4-one, 2-(4-Biphenylyl)-3-cyano-1-ethoxycarbonyl-4H-quinolizin-4-one, 2-(4-Bromophenyl)-3-cyano-1-ethoxycarbonyl-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-(4-tert-butylphenyl)-4H-quinolizin-4-one, 3-Cyano-2-(3,4-dimethoxyphenyl)-1-ethoxycarbonyl-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-(4-methoxyphenyl)-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-(4-methylphenyl)-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-(3,4-methylenedioxyphenyl)-4H-quinolizin-4-one, 3-Cyano-2-(2,4-dichlorophenyl)-1-ethoxycarbonyl-4H-quinolizin-4-one, 3-Cyano-2-phenyl-1-propoxycarbonyl-4H-quinolizin-4-one, 3-Cyano-1-methoxycarbonyl-2-phenyl-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-(4-fluorophenyl)-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-(3-fluoro-4-methylphenyl)-4H-quinolizin-4-one, 3-Cyano-2-(3,4-dimethylphenyl)-1-ethoxycarbonyl-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-(4-ethoxyphenyl)-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-(4-isopropoxyphenyl)-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-(3-methoxyphenyl)-4H-quinolizin-4-one, 2-(4-Benzyloxyphenyl)-3-cyano-1-ethoxycarbonyl-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-(3,4,5-trimethoxyphenyl)-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-(4-nitrophenyl)-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-(2-methoxyphenyl)-4H-quinolizin-4-one, 2-(3-Bromophenyl)-3-cyano-1-ethoxycarbonyl-4H-quinolizin-4-one, 2-(3-Benzyloxy-4-methoxyphenyl)-3-cyano-1-ethoxycarbonyl-4H-quinolizin-4-one, 2-(4-Benzyloxy-3-methoxyphenyl)-3-cyano-1-ethoxycarbonyl-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-(4-methylthiophenyl)-4H-quinolizin-4-one, 2-(4-Acetylaminophenyl)-3-cyano-1-ethoxycarbonyl-4H-quinolizin-4-one, 2-(4-Benzoylphenyl)-3-cyano-1-ethoxycarbonyl-4H-quinolizin-4-one, 3-Cyano-2-(2,3-dimethoxyphenyl)-1-ethoxycarbonyl-4H-quinolizin-4-one, 3-Cyano-2-(3,5-dimethoxyphenyl)-1-ethoxycarbonyl-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-(4-hydroxyphenyl)-4H-quinolizin-4-one, 3-Cyano-2-(3,4-dihydroxyphenyl)-1-ethoxycarbonyl-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-(4-hydroxy-3-methoxyphenyl)-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-(3-hydroxy-4-methoxyphenyl)-4H-quinolizin-4-one, 2-(4-Aminophenyl)-3-cyano-1-ethoxycarbonyl-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-piperidino-4H-quinolizin-4-one, 3-Cyano-1-(3-phenylpropoxycarbonyl)-2-piperidino-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-(1-pyrrolidinyl)-4H-quinolizin-4-one, 3-Cyano-1-(3-phenylpropoxycarbonyl)-2-(1-pyrrolidinyl)-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-[4-(2-hydroxyethyl)-piperazin-1-yl]-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-(4-formylpiperazin-1-yl)-4H-quinolizin-4-one, 3-Cyano-2-(4-formylpiperazin-1-yl)-1-(3-phenylpropoxycarbonyl)-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-(4-methylpiperazin-1-yl)-4H-quinolizin-4-one, 3-Cyano-2-(4-methylpiperazin-1-yl)-1-(3-phenylpropoxycarbonyl)-4H-quinolizin-4-one, 2-(4-Benzylpiperidino)-3-cyano-1-ethoxycarbonyl-4H-quinolizin-4-one, 2-(4-Benzylpiperidino)-3-cyano-1-(3-phenylpropoxycarbonyl)-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-(4-phenylpiperidino)-4H-quinolizin-4-one, 3-Cyano-2-(4-phenylpiperidino)-1-(3-phenylpropoxycarbonyl)-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-morpholino-4H-quinolizin-4-one, 3-Cyano-2-morpholino-1-(3-phenylpropoxycarbonyl)-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-(imidazol-1-yl)-4H-quinolizin-4-one, 3-Cyano-2-(imidazol-1-yl)-1-(3-phenylpropoxycarbonyl)-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-(1,3,4-triazol-1-yl)-4H-quinolizin-4-one, 3-Cyano-1-(3-phenylpropoxycarbonyl)-2-(1,3,4-triazol-1-yl)-4H-quinolizin-4-one, 3-Cyano-2-[4-(2-hydroxyethyl)piperazin-1-yl]-1-(3-phenylpropoxycarbonyl)-4H-quinolizin-4-one, 3-Cyano-1-ethoxycarbonyl-2-(4-morpholinocarbonylmethylpiperazin-1-yl)-4H-quinolizin-4-one, 3-Cyano-2-(4-morpholinocarbonylmethylpiperazin-1-yl)-1-(3-phenylpropoxycarbonyl)-4H-quinolizin-4-one, 3-Cyano-1-(2-hydroxyethyloxycarbonyl)-2-piperidino-4H-quinolizin-4-one, and the pharmaceutically acceptable salts thereof. 7. A 4H-quinolizin-4-one derivative as claimed in any one of claims 1 to 3 for use in the treatment of allergic bronchial asthma, allergic rhinitis, atopic dermatitis or hypersensitive diseases. 8. A 4H-quinolizin-4-one as claimed in any one of claims 1 to 3 for use in the preparation of a medicament for use in the treatment of allergic bronchial asthma, allergic rhinitis, atopic dermatitis or hypersensitive diseases.

Inventors: KURASHINA, YOSHIKAZU, MIYATA, HIROSHI, MOMOSE, DEN-ICHI
Applicants: KISSEI PHARMACEUTICAL CO., LTD.
Application year: 1988
Main classification: C07D455
IPC codes: C07D455